Background: Brucellosis is one of the ultimate well-known zoonotic diseases and is endemic in many cultivated countries affecting both humans and livestock. In humans’ obstacles of brucellosis are continuous fever, joint pain, sweating, weakness, fatigue, headache, chest pain and abdominal pain. Toxoplasmosis is a parasitic infection caused by a protozoan apicomplexan parasite named Toxoplasma gondii. Though it is symptomless but in severity it causes encephalitis, myocarditis, and pneumonia. Methods: The study aim was to accomplish the serological prevalence of Brucella melitensis and Toxoplasma gondii in butchers processed through ICT and serum agglutination tests. For this purpose, 270 blood samples were randomly collected from active butchers at seven different union councils of district Karak. The blood samples were examined for brucellosis and toxoplasmosis based on serum slide agglutination and immune chromatographic tests. SPSS version 22 for windows will be used for the analysis of data. Results: The overall prevalence of brucellosis and toxoplasmosis was 15.6% and 21.9%, respectively. Furthermore, a higher prevalence of brucellosis and toxoplasmosis was found in butchers with age group (15-31 years) 7.4% and 8.1% and weight group (63kg-80kg) 7.4% and 10.7%. In conclusion, brucellosis is a significant public health problem in and around district Karak. Conclusion: This disease can be forestalling, especially in rural areas, through preventive measures. It is endorsed that public health supremacy should enlighten the public about the prevention and control of brucellosis and toxoplasmosis. Keywords: Brucella melitensis; Toxoplasma gondii; Prevalence; Butcher; Karak
Salmonella paratyphi A harbors gall bladder in the human body. It serves as a site of persistence for Salmonella paratyphi A. It is an enteric pathogen which has become resistant to many drugs. Therefore, the current study was designed for the identification and antibiogram analysis of S. paratyphi A, isolated from the gall bladder patients undergone cholecystectomy. It included 250 samples of bile, stone, and tissue of patients. The samples were cultured on blood, macConkey, and Salmonella Shigella media. Further identification was carried out by morphological oxidase test and Analytical Profile Index (API) strips, followed by antibiogram analysis of the isolates. In the current study, twenty-eight (11.2%) paratyphi A were isolated including 10 (10%) from male patients and 18 (12%) from female patients. Furthermore, 96 samples were found to be positive for miscellaneous growth including 53 with S. typhi (21.2%), 13 with Escherichia coli (5.2%), 09 with Klebsiella (3.6%), 07 with Providencia (2.8%), 05 with Pseudomonas (2%), 03 with Proteus (1.2%), and 06 with Staphylococcus aureus (2.4%). The distribution and susceptibility pattern of S. paratyphi A isolates was checked in different types of clinical specimens including bile, stones, tissue, bile/stones, bile/tissue, stones/tissue, and bile/stone/tissue. S. paratyphi A was distributed as follows: bile (11), stones (5), tissue (3), bile/ stones (4), stones/ tissue (1), bile/tissue (1), and bile/stones/tissue (3). The results of the antibiogram analysis found that the isolates of Paratyphi A were resistant to sulfamethoxazole 23 (82.14%), cefixime 23 (82.14%), ceftriaxone (rocephin) 20 (71.42%), augmentin 19 (67.85%), and azithromycin 18 (64.28%). The increased susceptibility of these isolates was towards meronem 28 (100%), imipenem 28 (100%), cefoperazon + sulbactam (sulzone) 25 (89.28%), and amikacin 23 (82.14%). The current study signifies the use of the most susceptible and effective antibiotic options for gall bladder diseases complicated by S. paratyphi A, which showed resistance to ceftriaxone (rocephin), cefixime, sulfamethoxazole, azithromycin, and augmentin, while sensitivity to meropenem, imipenem, cefoperazone + sulbactam (sulzone), and amikacin. It makes the latter a better choice for treatment against the gall stone disease complicated with S. paratyphi A infection.
Enzyme-linked immunosorbent assay (ELISA) technique measures antigens, antibodies, and protein reactions in biological samples by enzymatic reactions. The chemiluminescence immunoassay (CLIA) technique determines sample concentrations based on the intensity of the light emitted by a chemical and biological reaction. This review provides an overview to understand the ELSIA and CLIA methods with their types and comparison. ELISA and CLIA methods were compared based on previous literature studies. In conclusion, CLIA is found highly sensitive, specific, and rapid, as compared to ELISA, but CLIA is an expensive method as compared to ELISA.
The current study attempts the phenotypic and molecular detection of the virulence factors of Proteus mirabilis clinical isolates. A total of 600 urine samples were collected from urinary tract-infected patients at Khyber Teaching Hospital, Peshawar, Pakistan. P. mirabilis isolates were identified through different biochemical tests. Virulence factors including urease production, biofilm formation, and swarming phenomenon were determined by using different markers (ureC1, rsbA, and luxS genes), identified via the polymerase chain reaction (PCR) technique. Out of the selected samples, 95 samples (15.83%) were identified as P. mirabilis. The molecular study showed that all isolates (100%) possessed the ureC gene. Whereas, 90.52% and 92.63% of the isolates gave positive results for biofilm formation (rsbA gene) and swarming phenomenon (luxS gene), respectively. The phenotypic and molecular study of P. mirabilis virulence factors provides a better understanding of how P. mirabilis infection spreads. The results could be used for prevention and improvements in its clinical treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.